http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
-
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
-
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - K
-
Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024
-
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
-
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
-
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
-
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
-
Entera Bio Ltd. (ENTX) Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program
-
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Mont
-
Entera Bio Ltd. (ENTX) Announces Robust Pharmacokinetic Data for Oral GLP-2 Peptide Tablet Treatment
-
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
-
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
